Based on the information received at the completion of the clinical evaluation, there were not enough evidence to support the following case event of an endoleak type 3b or to confirm the patient's secondary procedure (with a non-endologix device) as it was originally reported.It was noted that the original device is still implanted.A follow up was made to the patient post surgery and the patient is currently doing well and in stable condition.Cumulative knowledge informed by past assessments of similar complaints was applied to a review of the available medical information.The most likely cause of the compromised stent graft integrity could not be determined due to lack of information surrounding the initial implant procedure and the secondary endovascular procedure.Procedure related harms and final patient disposition could not be ascertained.Reportedly, the patient was in stable condition after the secondary repair procedure.To date there has been no reports of further negative patient sequelae.A root cause investigation was carried out for all afx complaints having an identified failure mode of a type iiib endoleak.Endologix implemented the following corrective actions with the intent of reducing type iiib endoleak events; upgraded graft material (i.E.Duraply) and updates to the ifu and additional physician training.The change to duraply graft material and the ifu changes were put in place july 2014.The type iiib endoleak rate for afx manufactured and implanted before these corrective actions were put in place is trending at 2.5%.Since the corrective actions were implemented, the type iiib endoleak events reported for afx devices has been reduced to less than 0.2%.In addition, the review of manufacturing lot confirmed all devices met specifications prior to release.The devices remain implanted in the patient and were not returned and no evaluation was completed.These types of events will be monitored and trended as part of the quality system.
|